Pyxis Oncology (NASDAQ:PYXS) Announces Quarterly Earnings Results

Pyxis Oncology (NASDAQ:PYXS) issued its quarterly earnings results on Thursday. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.06), Zacks reports.

Pyxis Oncology Stock Down 5.3%

NASDAQ:PYXS traded down $0.17 on Thursday, hitting $3.01. The stock had a trading volume of 1,264,919 shares, compared to its average volume of 1,623,279. Pyxis Oncology has a 52-week low of $1.03 and a 52-week high of $5.55. The stock has a market cap of $190.68 million, a price-to-earnings ratio of -2.30 and a beta of 1.31. The business’s 50-day simple moving average is $2.53 and its two-hundred day simple moving average is $1.96.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on PYXS. Wedbush started coverage on Pyxis Oncology in a research report on Tuesday, May 5th. They issued an “outperform” rating and a $6.00 price objective on the stock. Wells Fargo & Company began coverage on shares of Pyxis Oncology in a research report on Monday, August 3rd. They issued an “overweight” rating and a $12.00 target price for the company. Leerink Partners cut their target price on shares of Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating on the stock in a research note on Thursday, July 2nd. Weiss Ratings cut shares of Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 30th. Finally, Wall Street Zen lowered Pyxis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $7.50.

Institutional Trading of Pyxis Oncology

Several institutional investors have recently made changes to their positions in PYXS. Bank of America Corp DE raised its position in shares of Pyxis Oncology by 20.3% during the 4th quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock valued at $84,000 after buying an additional 9,062 shares in the last quarter. Acadian Asset Management LLC bought a new position in shares of Pyxis Oncology during the 1st quarter valued at approximately $81,000. XTX Topco Ltd bought a new stake in Pyxis Oncology in the second quarter worth $40,000. Marshall Wace LLP purchased a new position in Pyxis Oncology during the second quarter worth $163,000. Finally, Qube Research & Technologies Ltd boosted its stake in shares of Pyxis Oncology by 128.4% during the 2nd quarter. Qube Research & Technologies Ltd now owns 103,063 shares of the company’s stock worth $113,000 after purchasing an additional 57,935 shares during the period. Hedge funds and other institutional investors own 39.07% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical?stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody?drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off?target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early?stage ADC candidates directed against a variety of solid tumor antigens.